HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Pharmaceuticals

Market Closed - Toronto S.E. 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
4 CAD +10.50% Intraday chart for HLS Therapeutics Inc. +1.27% +1.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022 MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024 CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan MT
HLS Therapeutics Inc. Announces CFO Changes CI
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson MT
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo MT
HLS Therapeutics Brief: Says New REDUCE-IT Analyses Show Vascepa (Icosapent Ethyl) Associated with 29% Relative Risk Reduction Vs Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline MT
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses CI
HLS Therapeutics Inc.'s Equity Buyback announced on November 10, 2022, has expired. CI
HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00 MT
HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022. CI
HLS Therapeutics Inc. announces an Equity Buyback for 1,607,892 shares, representing 5% of its issued share capital. CI
Transcript : HLS Therapeutics Inc., Q3 2023 Earnings Call, Nov 09, 2023
HLS Therapeutics Reports Q3 2023 Revenue of US$16.0 Million, Renews Normal Course Issuer Bid MT
HLS Therapeutics Brief: Q3 2023 revenue was US$16.0 million, Adjusted EBITDA was $5.1 million and cash from operations was $5.4 million; Renewing Normal Course Issuer Bid MT
North American Morning Briefing : Traders Await -2- DJ
HLS Therapeutics Inc. authorizes a Buyback Plan. CI
Chart HLS Therapeutics Inc.
More charts
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.956 USD
Average target price
4.849 USD
Spread / Average Target
+64.07%
Consensus
  1. Stock
  2. Equities
  3. Stock HLS Therapeutics Inc. - Toronto S.E.
  4. News HLS Therapeutics Inc.
  5. HLS Therapeutics Brief: Announcing that Vascepa Now Reimbursed by the Saskatchewan Drug Plan